Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegLiposomal Doxorubicin (PLD) and Carboplatin in Gynecological Sarcomas
NCT00815945Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Jun 2008
- Primary completion
- Nov 2011
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and carboplatin in uterine sarcoma, ovarian carcinosarcoma (OCS), leiomyosarcoma (LMS) and 1 more, sponsored by AGO Study Group. Primary endpoint: Progression-Free Survival. Started Jun 2008; status: completed.
02
Drugs
pegylated liposomal doxorubicincarboplatin
03
Conditions
uterine sarcomaovarian carcinosarcoma (OCS)leiomyosarcoma (LMS)mesenchymal tumor
Beyond the preview
Go deeper on NCT00815945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00815945.